Incidence of venous thromboembolism (VTE) among postmenopausal women prescribed ospemifene, selective oestrogen receptor modulators (SERM), or untreated vulvar and vaginal atrophy

Ospemifene is a non-steroidal selective oestrogen receptor modulator (SERM) for moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) due to menopause. An ongoing EU post-authorization safety study estimated the incidence of venous thromboembolism (VTE) in a cohort of postmenopausal women prescribed ospemifene, other SERM (raloxifene, bazedoxifene, or tamoxifen, for non-cancer indications), or untreated VVA.

Source: Maturitas - May 14, 2019 Category: Primary Care Authors: Bin Cai, Beth Nordstrom, Yuki Yoshida, Nafeesa Dhalwani, Fabio De Gregorio, Trevor Gibbs Tags: P36 Source Type: research